4BIO Ventures II Fund

https://www.4biocapital.com

4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces 9 September 2019 that it has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been committed from family offices and institutional investors. The Group is targeting $150 million for the final close by the second half of 2020. 4BIO Ventures II will invest in 8 to 12 private companies developing advanced therapies – such as cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome – in areas of high unmet need. The Group’s objective is to build, support and grow early stage companies with the ultimate goal of ensuring sustainable access to these potentially curative therapies for all patients. The fund will be focused solely on advanced therapies without geographic limit, giving investors undiluted access to the fastest growing field of medicine. *

	Start	2019-09-09 closing, first
	Group	4BIO Ventures (4BIO Capital) (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	78 Pall Mall
	City	SW1Y 5ES London
	Tel	+44-203-427-5500
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	50,000,000 (first closing (2019) 2019-09-09)


		Record changed: 2021-02-21